Drug intelligence / Profile preview

Myostatin inhibitory-D-peptide-35

Development stage: Preclinical
Modality: Peptides
Administration: Transdermal, Intramuscular

Overview

Myostatin inhibitory-D-peptide-35 (MID-35) is a peptide therapeutic agent under investigation for the treatment of sarcopenia, a public health issue affecting older adults characterized by skeletal muscle loss. The drug functions by inhibiting myostatin, a protein known to limit muscle growth. It is being developed for non-invasive intramuscular delivery via iontophoresis, a transdermal drug delivery technology that uses weak electricity to facilitate the passage of macromolecules from the skin surface to skeletal muscle.

Targets

TGFB1 (Transforming growth factor Beta-1 proprotein)GDF8 (Myostatin)Activin AGDF11 (Growth differentiation factor 11)

Beyond the preview

Go deeper on Myostatin inhibitory-D-peptide-35.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Myostatin inhibitory-D-peptide-35.

Explore the full profile